PAVmed Achieves Global Healthcare Milestone with PortIO™ Trials in Colombia
NEW YORK, BUSINESS WIRE – PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a leader in diversified medical technology, has reported successful implantations of its groundbreaking PortIO™ Intraosseous Infusion System. These first-ever human implantations took place at Clinica Porto Azul in Barranquilla, Colombia, involving three patients as part of an IRB-approved study set to include up to 40 participants. The procedures, along with subsequent infusions, were performed without any complications, adhering fully to the study’s protocols.
Dr. David Sabbag, an interventional radiologist at Clinica Porto Azul, remarked on the procedure: "Introducing PortIO™ has significantly advanced vascular access technology. The implantation process was straightforward, and the patients handled both the procedure and the infusions quite well. PortIO™ is set to be the first long-term vascular access device that operates without the need for routine maintenance, a notable improvement over traditional devices that require frequent, sometimes risky maintenance to prevent clotting."
Brian J. deGuzman, M.D., Chief Medical Officer at PAVmed, who led the physician training and attended the implantations, noted: "The device functioned flawlessly, fulfilling its intended design and purpose. While the intraosseous pathway for infusions has been used historically, existing devices are short-term and not suited for extended use. PortIO™ innovates by offering a long-term solution free from the common limitations, including the need for frequent maintenance to ensure functionality."
The PortIO™ system includes an implantable device and an insertion kit, designed for direct insertion into the bone, thus providing immediate access to the bone marrow for delivering medications and fluids. This method avoids invasive surgery and doesn't require x-ray verification, streamlining vascular access and eliminating common complications associated with traditional methods. PortIO™ not only enhances the quality of life for patients with difficult venous access or those undergoing renal dialysis but also represents a significant advancement for patients with adverse reactions to common anticoagulants such as heparin.
About PAVmed
PAVmed Inc. is a trailblazer in medical technology, operating across medical devices, diagnostics, and digital health sectors. Its prominent subsidiary, Lucid Diagnostics Inc., markets unique tools for the early detection of esophageal cancer. Another key subsidiary, Veris Health Inc., is developing an implantable vascular access port equipped with biologic sensors and wireless communication, optimizing cancer treatment through remote patient monitoring. PAVmed has also introduced products such as CarpX® for carpal tunnel syndrome and continues to innovate with devices like EsoCure™ and NextFlo™. For more information about PAVmed and its innovations, visit www.pavmed.com.
Discover more about this pioneering innovation and its impact on the future of vascular access. Click the button below to read more details and stay updated on this exciting development. Keep up with how PAVmed is making a difference in the medical field, directly from Colombia.
